Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

Antiviral Research

Volumn 70, Issue 3, 2006, Pages 121-131

  Ilyushina, Natalia A ^a,b   Bovin, Nicolai V ^c   Webster, Robert G ^a,d   Govorkova, Elena A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Amantadine; Drug resistance; Influenza A virus; Oseltamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; HEMAGGLUTININ; PROTEIN M2; SIALIC ACID; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL STRAIN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG SENSITIVITY; IN VITRO STUDY; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS CULTURE; VIRUS MUTATION; VIRUS RESISTANCE;

ACETAMIDES; AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MUTATION; OSELTAMIVIR; PLAQUE ASSAY;

ORTHOMYXOVIRIDAE;

EID: 33646784370     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.01.012     Document Type: Article

References (45)

1. Blick T.J., Sahasrabudhe A., McDonald M., Owens I.J., Morley P.J., Fenton R.J., and McKimm-Breschkin J.L. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-Guanidino-Neu5Av2en. Virology 246 (1998) 95-103
2. Bovin N.V., Korchagina E.Yu., Zemlyanukhina T.V., Byramova N.E., Galanina O.E., Zemlyakov A.E., Ivanov A.E., Zubov A.E., and Mochalova L.V. Synthesis of polymeric neoglycoconjugates based on N-substituted polyacrylamides. Glycoconj. J. 10 (1993) 142-151
3. Bright R.A., Medina M., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
4. Claas E.C., Osterhaus A.D.M.E., Van Beek R., De Long J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., and Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 (1998) 472-477
5. Eisen M.B., Sabesan S., Skehel J.J., and Wiley D.C. Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystrallography. Virology 232 (1997) 19-31
6. Gambaryan A.S., and Matrosovich M.N. A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J. Virol. Meth. 39 (1992) 111-123
7. Gubareva L.V., Bethell R., Hart G.J., Murti K.G., Penn C.R., and Webster R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-Guanidino-Neu5Ac2en. J. Virol. 70 (1996) 1818-1827
8. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998) 1257-1262
9. Govorkova E.A., Fang H.B., Tan M., and Webster R.G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48 (2004) 4855-4863
10. Hay A.J., Wolstenholm A.J., Skehel J.J., and Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4 (1985) 3021-3024
11. Hayden F.G., Cote K.M., and Douglas R.G. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17 (1980) 865-870
12. Hayden F.G., Douglas R.G., and Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother. 18 (1980) 536-541
13. Hayden F.G., and Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176 (1992) 119-130
14. Hayden F.G. Amantadine and rimantadine-clinical aspects. In: Richman D.D. (Ed). Antiviral Drug Resistance (1996), Wiley, New York 59-77
15. Hayden F.G. Prospectives on antiviral use during pandemic influenza. Phil. Trans. R. Soc. London 356 (2001) 1877-1884
16. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 (2004) 1627-1630
17. Hoffmann E., Stech J., Guan Y., Webster R.G., and Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146 (2001) 2275-2289
18. Ilyushina N.A., Govorkova E.A., and Webster R.G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 341 (2005) 102-106
19. Kaverin N.V., Matrosovich M.N., Gambaryan A.S., Rudneva I.A., Shilov A.S., Varich N.L., Makarova N.V., Kropotkina E.A., and Sinitsin B.V. Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. Virus Res. 66 (2000) 123-129
20. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
21. Klimov A.I., Rocha E., Hayden F.G., Shult P.A., Roumillat L.F., and Cox N.J. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 172 (1995) 1352-1355
22. Lew W., Chen X., and Kim C.U. Discovery and development of GS4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7 (2000) 663-672
23. Madren L.K., Shipman C., and Hayden F.G. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir. Chem. Chemother. 6 (1995) 109-113
24. Matrosovich M.N., Gambaryan A.S., Tuzikov A.B., Byramova N.A., Mochalova L.V., Golbraikh A.A., Shenderovich M.D., Finne J., and Bovin N.V. Probing of the receptor-binding sites of the H1 and H3 influenza virus hemagglutinins by synthetic and natural sialosides. Virology 196 (1993) 111-123
25. Matrosovich M.N., Zhou N., Kawaoka Y., and Webster R.G. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J. Virol. 73 (1999) 1146-1155
26. McKimm-Breschkin J.L., Blick T.J., Sahasrabudhe A., Tiong T., Marshall D., Hart G.J., Bethell R.C., and Penn C.R. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40 (1996) 40-46
27. McKimm-Breschkin J.L. Resistance of influenza viruses to neraminidase inhibitors-a review. Antivir. Res. 47 (2000) 1-17
28. McKimm-Breschkin J.L. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat. Respir. Med. 4 (2005) 107-116
29. Monto A.S., Fleming D.M., Henry D., de Groot R., Makela M., Klein T., Elliott M., Keene O.N., and Man C.Y. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. 180 (1999) 254-261
30. Monto A.S. The role of antivirals in the control of influenza. Vaccine 21 (2003) 1796-1800
31. Nobusawa E., Aoyama T., Kato H., Suzuki Y., Tateno Y., and Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182 (1991) 475-485
32. Pinto L.H., Holsinger L.J., and Lamb L.A. Influenza virus M2 protein has ion channel activity. Cell 69 (1992) 517-528
33. Potier M., Mameli L., Belislem M., Dallaire L., and Melanxon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-d-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979) 287-296
34. Rogers G.N., Paulson J.C., Daniels R.S., Skehel J.J., Wilson I.A., and Wiley D.C. Single amino acid substitutions in influenza hemagglutinin change receptor binding specificity. Nature 304 (1983) 76-78
35. Scholtissek C., Quack G., Klenk H.-D., and Webster R.G. How to overcome resistance of influenza A viruses against adamantane derivatives?. Antivir. Res. 37 (1998) 83-95
36. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188 (2003) 57-61
37. Smee D.F., Bailey K.W., Morrison A.C., and Sidwell R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48 (2002) 88-93
38. Stephenson I., and Nicholson K.G. Influenza: vaccination and treatment. Eur. Respir. J. 17 (2001) 1282-1293
39. Varghese J.H., McKimm-Breschkin J.L., Caldwell J.B., Kortt A.A., and Colman P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14 (1992) 327-332
40. von Itzstein M., Wu W.-Y., Kok G.K., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smithe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., and Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus protection. Nature 363 (1993) 418-423
41. Ward P., Small I., Smith J., Suter P., and Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 (2005) 5-21
42. Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., and Wiley D.C. Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. Nature 333 (1988) 426-431
43. Wilson S.Z., Knight V., Wyde P.R., Drake S., and Couch R.B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 17 (1980) 642-648
44. World Health Organization. Avian influenza A (H5N1). Weekly Epidemiol. Rev. 79 (2004) 65-70
45. Ziegler T., Hemphill M.L., Ziegler M.L., Perez-Oronoz G., Klimov A.I., Hampson A.W., Regnery H.L., and Cox N.J. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 180 (1999) 935-939